VALSTAR PRESERVATIVE FREE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VALSTAR PRESERVATIVE FREE (VALSTAR PRESERVATIVE FREE).
Valrubicin is a semisynthetic anthracycline derivative that intercalates into DNA, inhibiting nucleic acid synthesis and inducing cell death. It is cytotoxic to both dividing and non-dividing cells.
| Metabolism | Valrubicin is primarily metabolized in the liver to its active metabolite, N-trifluoroacetyladriamycin, via enzymatic reduction. Minimal systemic absorption occurs after intravesical administration. |
| Excretion | Renal: approximately 50-70% excreted unchanged in urine within 72 hours; biliary/fecal: minor (<5%). |
| Half-life | Terminal elimination half-life: 3-5 hours; clinical context: supports intravesical instillation with minimal systemic absorption. |
| Protein binding | Approximately 50-60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | After intravesical administration, systemic absorption limited; apparent Vd is approximately 0.8-1.5 L/kg following IV administration (not clinically used IV); clinical meaning: extensive tissue distribution including bladder mucosa. |
| Bioavailability | Intravesical: negligible systemic bioavailability (<1%) due to limited absorption across bladder epithelium. |
| Onset of Action | Intravesical: clinical effect begins within 24-48 hours; systemic absorption is negligible. |
| Duration of Action | Intravesical: therapeutic effect persists for approximately 30-60 minutes post-instillation; recommended dwell time is 1-2 hours. |
| Molecular Weight | 723.82 |
Intravesical instillation of 800 mg (40 mL of 20 mg/mL solution) weekly for 6 weeks, retained in bladder for 2 hours.
| Dosage form | SOLUTION |
| Renal impairment | Valstar is not absorbed systemically after intravesical administration; no dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required based on hepatic function; systemic absorption is negligible. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no standard dosing recommendations available. |
| Geriatric use | No specific dose adjustment for elderly patients; intravesical administration results in minimal systemic exposure. |
| 1st trimester | Contraindicated: valrubicin is a cytotoxic agent with potential teratogenic effects. Animal studies have shown embryotoxicity and fetal malformations. Pregnancy should be excluded before administration. |
| 2nd trimester | Contraindicated: Similar risks as first trimester. Avoid use unless absolutely necessary. |
| 3rd trimester | Contraindicated: Can cause fetal harm; avoid use during pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for VALSTAR PRESERVATIVE FREE (VALSTAR PRESERVATIVE FREE).
| Placental transfer | Based on molecular weight (723.82 Da) and lipophilicity, valrubicin is expected to cross the placenta. No human data available, but animal studies show transfer. |
| Breastfeeding | It is not known whether valrubicin is excreted in human milk. Due to potential serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment and for a period after the last dose. |
■ FDA Black Box Warning
Valstar (valrubicin) should not be used for patients with a known hypersensitivity to valrubicin or any component of the product, or with concurrent urinary tract infection. It should not be used in patients with a perforated bladder, compromised bladder mucosa, or bladder capacity less than 100 mL.
| Serious Effects |
Hypersensitivity to valrubicin or any component of the formulationActive urinary tract infectionSmall bladder capacity (not amenable to instillation)Known or suspected pregnancy
| Precautions | Contains benzyl alcohol, which has been associated with gasping syndrome in neonates. Not recommended for use in pregnant women. Monitor for bladder irritation, hematuria, and urinary tract infection. Evaluate for bladder contracture. Consider cystectomy if no response. |
| Food/Dietary | No specific food interactions, but advise avoiding bladder irritants such as caffeine, spicy foods, alcohol, and acidic juices (e.g., orange juice) during treatment course to minimize bladder discomfort. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Valstar (valrubicin) is FDA Pregnancy Category C. Intravesical administration results in negligible systemic absorption, minimizing fetal exposure. No adequate human studies exist. First trimester: potential risk unknown; avoid unless benefit outweighs risk. Second and third trimesters: unlikely to cause fetal harm due to low systemic levels. However, data insufficient to confirm safety. |
| Fetal Monitoring | No specific fetal monitoring required due to low systemic absorption. Monitor for local adverse effects (bladder irritation, hematuria). In pregnant patients, standard obstetric monitoring is advised. No need for valrubicin plasma level monitoring. |
| Fertility Effects | Valrubicin is an anthracycline derivative with potential gonadotoxicity; however, intravesical administration limits systemic exposure. No specific human data on fertility. Animal studies have not been conducted with intravesical route. Consider risk of reduced fertility with systemic anthracyclines, but unlikely with local therapy. |
| Clinical Pearls | Valstar (valrubicin) is a intravesical agent used for BCG-refractory carcinoma in situ of the bladder. Administer as a 75 mg/750 mL intravesical instillation weekly for 6 weeks. The preservative-free formulation is essential for bladder instillation to avoid mucosal irritation. Ensure patient does not drink fluids for 8-12 hours before instillation to reduce urine dilution. After instillation, patient should retain the solution for 2 hours, rotating positions every 30 minutes to maximize mucosal contact. Monitor for bladder spasms, dysuria, and hematuria. Avoid extravasation; if occurs, treat symptomatically. |
| Patient Advice | Do not eat or drink anything for at least 8 hours before each treatment to ensure the bladder is empty and the medication stays in contact with the bladder lining. · After the medication is instilled, you must hold it in your bladder for 2 hours. During this time, lie down and rotate positions every 30 minutes (left side, right side, back, stomach) to spread the drug. · You may experience bladder spasms, pain, or blood in urine; report these to your doctor. Some burning with urination is common. · Drink plenty of fluids after the 2-hour hold period to flush the bladder, but avoid excessive caffeine or acidic drinks that may irritate the bladder. · Do not have sexual intercourse during the treatment course and for 1 week after the last dose, and use barrier contraception if needed. · Contact your doctor immediately if you have severe pelvic pain, difficulty urinating, or signs of infection (fever, chills). |